Biodesix (BDSX) Stock Price, News & Analysis

Biodesix, Inc. (BDSX) is a diagnostic solutions company that focuses on improving clinical care and outcomes for patients with lung disease and other cancers. The company’s primary activities center on diagnostic testing services and development services that support healthcare professionals and biopharmaceutical partners. Biodesix common stock trades on The Nasdaq Stock Market under the symbol BDSX.

According to company disclosures, Biodesix operates a single overall business focused on diagnostic testing, with revenue derived from diagnostic tests and from services provided to biopharmaceutical and life sciences organizations. The company emphasizes blood-based testing and molecular diagnostic approaches, and it reports that its diagnostic offerings and services are intended to support more personalized care decisions, particularly in lung disease and oncology.

Core diagnostic testing business

Biodesix states that its Biodesix Diagnostic Tests are marketed under the brands Nodify Lung® Nodule Risk Assessment and IQLung® Cancer Treatment Guidance. These tests are described as tools that support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Company communications highlight the use of these tests in lung nodule risk assessment and in guiding treatment decisions for lung cancer.

In its public updates, Biodesix reports that Lung Diagnostics revenue is a major component of its business. The company attributes growth in this area to increases in test volumes, improvements in average revenue per test, and reimbursement dynamics. It also notes activities to expand adoption of its lung diagnostic tests, including use in pulmonology and primary care settings, as well as evidence-generation efforts such as real-world studies and clinical and health economic research related to its Nodify Lung tests.

Development services for biopharmaceutical and research partners

Beyond clinical testing, Biodesix provides Development Services to biopharmaceutical companies, life sciences organizations, and research institutions. The company describes these services as enabling partners with scientific, technological, and operational capabilities that support the development of diagnostic tests, tools, and therapeutics. Public announcements reference development services related to clinical trial testing, diagnostic research, and the discovery, development, and commercialization of companion diagnostics.

Biodesix also reports collaborations around Droplet Digital PCR (ddPCR™) technology. For example, the company has disclosed an expanded partnership under which it will conduct development, clinical validation, and regulatory submissions of in vitro diagnostic assays for oncology applications using Bio-Rad’s Droplet Digital PCR technology. Under this type of arrangement, Biodesix has indicated that, following regulatory clearance, it expects to manufacture and distribute specimen collection kits for the developed assays and to offer certain assays as test services through its accredited laboratory for biopharma and clinical customers.

Focus on lung disease and oncology

Biodesix describes itself as being driven to improve care for patients with lung disease, and it highlights lung cancer and lung nodule management as central application areas for its tests. Company materials reference on-market Nodify Lung tests, including Nodify CDT® and Nodify XL2®, and describe real-world and clinical studies designed to characterize their performance and clinical utility in diverse patient populations.

In addition to lung disease, Biodesix has announced development work in breast cancer, including an ultra-sensitive ESR1 assay for monitoring treatment resistance in hormone receptor-positive, HER2-negative advanced breast cancers. The company has indicated that this assay is available to biopharmaceutical customers as part of its Development Services offering and that it is working with partners to clinically validate and potentially seek reimbursement for such assays.

Research, evidence generation, and scientific engagement

Biodesix regularly reports participation in scientific and medical conferences, including meetings focused on lung cancer, breast cancer, pharmacoeconomics, and molecular pathology. The company highlights poster presentations and workshops that address topics such as:

• Clinical utility data for Nodify Lung tests and their role in early lung cancer diagnosis.
• Health economic analyses of pulmonary nodule-related workup costs and resource utilization.
• Development of ultra-sensitive assays for monitoring cancer-related mutations in liquid biopsies.
• Molecular diagnostic approaches that incorporate technologies such as next-generation sequencing (NGS), droplet digital PCR, and mass spectrometry.

These activities are presented by the company as part of its efforts to expand the evidence base for its diagnostic tests and to collaborate with academic and industry partners on new diagnostic applications.

Financial reporting and business scale indicators

Biodesix provides regular financial updates through press releases and SEC filings. In its communications regarding 2025 results, the company reports revenue contributions from Lung Diagnostics and Development Services and discusses metrics such as test volumes, gross margins, and cash and cash equivalents. It also discloses use of non-GAAP measures such as Adjusted EBITDA as internal performance indicators, explaining that these measures are used by management to evaluate operating performance and to compare results across periods.

The company has also disclosed corporate actions related to its capital structure and stock listing, including a one-for-twenty reverse stock split of its common stock and subsequent confirmation from Nasdaq that it regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Global Market. These events are documented in Biodesix’s press releases and Form 8-K filings.

Regulatory and public company status

Biodesix, Inc. is incorporated in Delaware and files reports with the U.S. Securities and Exchange Commission. The company’s common stock, with a par value of $0.001 per share, is listed on The Nasdaq Stock Market under the trading symbol BDSX. SEC filings describe Biodesix as a public company subject to ongoing reporting obligations, and recent Form 8-K filings reference its principal executive offices in Louisville, Colorado.

As a diagnostics-focused business operating in the health care sector, Biodesix’s public communications emphasize its role in providing diagnostic tests and development services that support clinical decision-making, research, and therapeutic development, particularly in lung disease and oncology.